Key result
Lipoprotein apheresis reduced mean LDL-C levels by 73% in patients with familial hypercholesterolemia over a mean treatment duration of 13.9 years.
Why the study?
Familial hypercholesterolemia causes extremely high LDL-C levels and increased cardiovascular disease risk, motivating an evaluation of the efficacy and long-term outcomes of lipoprotein apheresis.
Does lipoprotein apheresis reduce LDL-C levels and impact cardiovascular events in patients with familial hypercholesterolemia?
Observational (n=13)
No
Does lipoprotein apheresis reduce LDL-C levels and impact cardiovascular events in patients with familial hypercholesterolemia?
Lipoprotein apheresis effectively reduces LDL-C levels by approximately 73% in high-risk familial hypercholesterolemia patients, though cardiovascular events may still occur.
Long-term apheresis achieved substantial LDL-C reduction in FH; leaves open cardiovascular event impact and requires prospective trials before practice change.
PURPOSE: Familial hypercholesterolemia (FH) is a genetic disorder associated with extremely high levels of low-density lipoprotein cholesterol (LDL-C) and increased incidence of cardiovascular disease. We aimed to evaluate the efficacy and long-term outcomes of lipoprotein apheresis (LA) in the treatment of FH. METHODS: Cardiovascular events that occurred before and after LA treatment were evaluated by reviewing previous medical records of patients with FH. RESULTS: Thirteen patients (female/male: 8/5) were included in this study. The mean Dutch score was 20±4. All patients were treated with a combination of statin and ezetimibe. Before the onset of LA, 8 patients had a history of coronary artery disease, and the median age at onset of cardiovascular disease (CVD) in these patients was 24 years. At the initiation of LA, the median age was 22 years and the mean LDL-C level was 410±130 mg/dL. The mean duration of LA treatment was 13.9±6.9 years. The mean LDL-C levels before and after the latest three LA treatments were 267±63.4 and 71.5±23.4 mg/dL, respectively. The mean reduction in LDL-C levels after LA was 73±8.2%. De novo cardiovascular events occurred in 10 patients during LA treatment; six of these patients had a known history of CVD before LA. Eight of these patients underwent invasive procedures for therapeutic purposes and the total number of procedures was 12. CONCLUSION: LA is an effective method of reducing LDL-C levels and an additional treatment option that may slow disease progression in patients with FH who are at high risk of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Hacışahinoğulları et al. (2024) conducted an observational in Familial hypercholesterolemia (n=13). Lipoprotein apheresis was evaluated on Cardiovascular events and LDL-C reduction. Lipoprotein apheresis reduced mean LDL-C levels by 73% in patients with familial hypercholesterolemia over a mean treatment duration of 13.9 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: